RT Journal Article
SR Electronic
T1 The spatio-temporal landscape of lung pathology in SARS-CoV-2 infection
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.10.26.20219584
DO 10.1101/2020.10.26.20219584
A1 André Figueiredo Rendeiro
A1 Hiranmayi Ravichandran
A1 Yaron Bram
A1 Steven Salvatore
A1 Alain Borczuk
A1 Olivier Elemento
A1 Robert Edward Schwartz
YR 2020
UL http://medrxiv.org/content/early/2020/10/27/2020.10.26.20219584.abstract
AB Recent studies have provided insights into the pathology and immune response to coronavirus disease 2019 (COVID-19)1–8. However thorough interrogation of the interplay between infected cells and the immune system at sites of infection is lacking. We use high parameter imaging mass cytometry9 targeting the expression of 36 proteins, to investigate at single cell resolution, the cellular composition and spatial architecture of human acute lung injury including SARS-CoV-2. This spatially resolved, single-cell data unravels the disordered structure of the infected and injured lung alongside the distribution of extensive immune infiltration. Neutrophil and macrophage infiltration are hallmarks of bacterial pneumonia and COVID-19, respectively. We provide evidence that SARS-CoV-2 infects predominantly alveolar epithelial cells and induces a localized hyper-inflammatory cell state associated with lung damage. By leveraging the temporal range of COVID-19 severe fatal disease in relation to the time of symptom onset, we observe increased macrophage extravasation, mesenchymal cells, and fibroblasts abundance concomitant with increased proximity between these cell types as the disease progresses, possibly as an attempt to repair the damaged lung tissue. This spatially resolved single-cell data allowed us to develop a biologically interpretable landscape of lung pathology from a structural, immunological and clinical standpoint. This spatial single-cell landscape enabled the pathophysiological characterization of the human lung from its macroscopic presentation to the single-cell, providing an important basis for the understanding of COVID-19, and lung pathology in general.Competing Interest StatementO.E. is scientific advisor and equity holder in Freenome, Owkin, Volastra Therapeutics and OneThree Biotech. R.E.S. is a member of the scientific advisory board of Miromatrix Inc. The remaining authors declare no competing financial interests.Funding StatementThis work was partially supported by the WorldQuant Initiative for Quantitative Prediction. A.R. is supported by a NCI T32CA203702 grant. O.E. is supported by Volastra, Janssen and Eli Lilly research grants, NIH grants UL1TR002384, R01CA194547, and Leukemia and Lymphoma Society SCOR 7012-16, SCOR 7021-20 and SCOR 180078-02 grants. R.E.S is supported by NIH grants NCI R01CA234614, NIAID 2R01AI107301 and NIDDK R01DK121072 and 1RO3DK117252. R.E.S. is supported as Irma Hirschl Trust Research Award Scholar.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Tissue Procurement Facility operates under Institutional Review Board (IRB) approved protocol and follows guidelines set by Health Insurance Portability and Accountability Act (HIPAA). Experiments using samples from human subjects were conducted in accordance with local regulations and with the approval of the IRB at the Weill Cornell Medicine. The autopsy samples were collected under protocol 20-04021814.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesRaw imaging mass cytometry data are available at a Zenodo repository: https://doi.org/10.5281/zenodo.4110560 Source code for data preprocessing and analysis is available at a GitHub repository: https://github.com/ElementoLab/covid-imc https://doi.org/10.5281/zenodo.4110560 https://github.com/ElementoLab/covid-imc